This week, we dissect the FDA's aggressive new stance on medical device cybersecurity, a shift causing major disruptions for manufacturers. What was once a recommendation is now a strict mandate, making cybersecurity documentation a primary reason for submission rejections and costly market entry delays.

We explore how this regulatory crackdown moves beyond simple compliance to demand a proactive, lifecycle-long security strategy. This is not just an IT problem anymore; it is a critical business and market access crisis that every MedTech leader needs to understand right now.

**Featured Case:**

A promising medical device company sees its multi-million dollar product launch indefinitely stalled. The reason? Not a clinical issue, but a failure to provide a complete Software Bill of Materials (SBOM) in their pre-market submission. This case highlights the critical pain point of underestimating documentation and how one missing piece can derail an entire project.

**This Episode's Insights:**

* Why is the FDA suddenly treating cybersecurity as a patient safety emergency?

* What is a Software Bill of Materials (SBOM) and why is it now a deal-breaker for new device submissions?

* How can a single documentation flaw lead to a "Refuse to Accept" letter from the FDA?

* Are your current post-market surveillance plans adequate for today's cyber threats?

* What is a Secure Product Development Framework and why is it essential for approval?

* How can you manage the cybersecurity lifecycle of a device once it's in the field?

* Why are legacy devices becoming a ticking time bomb for healthcare systems and manufacturers?

Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.